|

Allogeneic T cell progenitors, cultured ex-vivo Clinical Trials

2 actively recruiting trials across 1 location

Also known as: SMART101

Other1 trial

Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Phase 1/2

New York, New York1 trial

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

Memorial Sloan Kettering Cancer Center (MSKCC)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.